Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 52 No. 4
PSYCHOPHARMACOLOGY BULLETIN

VOL 52 No. 4

Articles in This Issue

ORIGINAL RESEARCH

Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies

Bryan Dirks, Maurizio Fava, Sarah D Atkinson, Mark Joyce, Michael E Thase, Becky Howell, Tim Lin, Serge Stankovic
Objective In a phase 2 study, pimavanserin demonstrated efficacy as adjunctive treatment for major depressive disorder (MDD). Subsequently, two phase 3 studies (NCT03968159 in the US; NCT03999918 in Europe) were initiated to examine the efficacy...
Pages 8-30 Read Article
ORIGINAL RESEARCH

A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5–12

Janet Wozniak, Abigail Farrell, Maura DiSalvo, Atilla Ceranoglu, Mai Uchida, Carrie Vaudreuil, Gagan Joshi, Stephen V Faraone, Emmaline Cook, Joseph Biederman
Objectives The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (FAs) and inositol alone and in combination for the treatment of pediatric bipolar (BP) spectrum disorder in young...
Pages 31-51 Read Article
DRUG DISPOSITION AND PHARMACOKINETICS

Association of CYP2D6*4 Polymorphism with the Steady- State Concentration of Haloperidol in Patients with Alcohol-Induced Psychotic Disorders

AA Parkhomenko, MS Zastrozhin, SA Pozdnyakov, VV Noskov, IA Zaytsev, VA Ivanchenko, NP Denisenko, KA Akmalova, V Yu Skryabin, EA Bryun, DA Sychev
CYP2D6 subfamily isoenzymes play an important role in the biotransformation of haloperidol, and their activity may influence the efficacy and safety of haloperidol. The use of haloperidol is often associated with the occurrence of adverse...
Pages 52-60 Read Article
COMPLICATED CASE HISTORY

Agomelatine Monotherapy for Autism—A Case Report

Ahmed Naguy, Saxby Pridmore, Mohammed A Jamali, Alaa Eisa Hasan, Bibi Alamiri
ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately,...
Pages 100-103 Read Article